Suven Pharmaceuticals
BSE: 543064 | NSE: SUVENPHAR | ISIN: INE03QK01018 | SECTOR: Biotechnology & DrugsOpen
652.45High
664.10Low
649.75Prev Close
644.85P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
168.43BVolume
3.15KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
660.45Ask
661.70
Company Description
- Biotechnology & Drugs
BSE
543064NSE
SUVENPHARISIN
INE03QK01018
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
Company Officers
Vaidheesh Annaswamy
Executive Chairman of the BoardSudhir Singh
Chief Executive OfficerHimanshu Agarwal
Chief Financial OfficerGaurav Bahadur
Chief Human Resource OfficerK. Rao
Compliance Officer, Company SecretaryVetukuri Venkata Prasada Raju
Managing Director, Additional Executive DirectorSubba Komaravolu
Chief Strategy OfficerBrian Shaughnessy
Chief Commercial Officer